Reardon MJ, et al. - In REPRISE III, the first large randomized comparison of two different transcatheter aortic valve replacement platforms (the mechanically expanded Lotus valve [Boston Scientific] and self-expanding CoreValve [Medtronic]), researchers assessed results of Lotus vs CoreValve after 2 years. In total, 912 high/extreme risk and severe, symptomatic aortic stenosis patients enlisted between September 22, 2014 and December 24, 2015 were randomized to receive either Lotus (607 [66.6%]) or CoreValve (305 [33.4%] at 55 centers in North America, Europe and Australia 2:1. According to findings, Lotus and CoreValve had comparable all-cause mortality rates, mortality or disabling stroke after 2 years. The Lotus arm favored disabling stroke, functional class, valve migration, and paravalvular leak; the CoreValve arm favored hemodynamic valve, thrombosis, and new implantation of pacemakers.